ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Biohaven to Proceed with Intranasal Vazegepant Trial for COVID-19 Lung Inflammation
April 14, 2020Biohaven Pharmaceutical announced it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant. -
Biohaven to Advance Vazegepant into Phase 3 for Acute Treatment of Migraine
March 26, 2020Biohaven Pharmaceutical announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant ... -
Biohaven Achieves Positive Topline Results in Migraine Study
December 18, 2019Biohaven Pharmaceutical announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial evaluating the efficacy and tolerability ...
Pharma Sources Insight January 2025
